poisar

Stocks · News reference

Braveheart Bio Presents 52-Week Phase 2 Data for BHB-1893 in Obstructive Hypertrophic Cardiomyopathy

Fiscal.ai

Braveheart Bio, Inc. reported long-term efficacy and safety data from a 52-week open-label extension study of its lead candidate, BHB-1893, at the American Heart Association Scientific Sessions 2026.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading